Key takeaways
- • Trial: Orforglipron Phase 2 (obesity) (NCT05051579) — Phase 2, 272 participants over 36 weeks.
- • Drug studied: Orforglipron (now approved as Foundayo) (Orforglipron (investigational)) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from baseline to week 26 (with 36-week assessment)
- • Key result: Up to 14.7% mean body-weight reduction at 36 weeks on the highest orforglipron dose versus 2.3% on placebo
- • Published: New England Journal of Medicine, 2023.
Study design
Orforglipron Phase 2 (obesity) was a phase 2 randomized controlled trial enrolling 272 participants over 36 weeks. The trial studied Orforglipron (now approved as Foundayo) (Orforglipron (investigational)) for obesity / overweight and was published in New England Journal of Medicine in 2023.
Primary endpoint
Percent change in body weight from baseline to week 26 (with 36-week assessment)
Key results
| Measure | Value |
|---|---|
| Headline result | Up to 14.7% mean body-weight reduction at 36 weeks on the highest orforglipron dose versus 2.3% on placebo |
| Mean weight loss (highest dose arm) | 14.7% |
| Participants | 272 |
| Duration | 36 weeks |
| Phase | Phase 2 |
Citation
Orforglipron Phase 2 (obesity). Published in New England Journal of Medicine, 2023.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Orforglipron (now approved as Foundayo) drug page — pricing, FDA status, side effects, alternatives
- All orforglipron (investigational) trials
- GLP-1 clinical trials database
Important: This trial was conducted on the FDA-approved branded product Orforglipron (now approved as Foundayo). Compounded versions of Orforglipron (investigational) have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.